Skip to content
Search

Latest Stories

AstraZeneca to stop developing Crohn's disease drug

Pb Staff writer
By Pb Staff writerJun 01, 2023
Pb Staff writer
See Full Bio

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape".

AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.

AbbVie will stop funding the drug's development, AstraZeneca said.

AbbVie's Skyrizi also treats Crohn's disease.

brazikumabskyrizicrohn’s diseaseabbvieallerganinflammatory bowelulcerative colitis.astrazeneca

Related News

National Insurance Contributions rise to 15%: What it means for community pharmacies
Guest Blog

Understanding the changes to National Insurance Contributions

CCA calls for urgent review of drug tariff to protect pharmacy
Gallery

CCA calls for urgent review of drug tariff to protect pharmacy

How to make your pharmacy travel clinic service a success
Guest Blog

Travel health clinic: A booster for revenue

Pharmacy First overly reliant on GP referrals
Gallery

Pharmacy First overly reliant on GP referrals

More For You

Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Asda pharmacy launches UK’s first adult earache service

Asda makes ear health more accessible for everyone

gettyimages

Asda pharmacy launches £25 adult earache service

British supermarket chain Asda has launched the “UK’s first” adult earache service, aiming to reduce the burden on NHS services by eliminating the need for a GP appointment.

Priced at £25, the service allows patients aged 18 and over to book same-day appointments with qualified Asda pharmacists at any of its 226 pharmacies in England.

Keep ReadingShow less
Dr Penelope Dash new chair of NHS England

Dr Penny Dash is currently the chair of the NHS North West London Integrated Care Board

parliamentlive

Dr Penelope Dash appointed as new chair of NHS England

Dr Penny Dash has been appointed as the next chair of NHS England following an open public appointment process.

She will succeed Richard Meddings, who is set to step down next month, and her four-year term begins on April 1, 2025.

Keep ReadingShow less
Nearly two-thirds of people think the NHS should be prioritised to receive more public spending in the future

Nearly two-thirds of people think the NHS should be prioritised to receive more public spending in the future

gettyimages

Over 70% public unaware of NHS 10-Year Health Plan – poll finds

Despite widespread promotion, nearly three-quarters (73%) of the English public remain unaware of the government’s 10-Year Health Plan for the NHS, according to new polling by the Health Foundation and Ipsos.

Once informed about the plan, just over a third (35%) expressed confidence that it would lead to improvements in the health service, while 59% remained unconvinced.

Keep ReadingShow less
Hospices receive £25 million for facility upgrades and refurbishments

The finding will help reform the palliative and end of life care system

gettyimages

Hospices receive £25 million for facility upgrades and refurbishments


The government has confirmed the release of £25 million for upgrades and refurbishments for hospices across England, as part of the biggest investment into hospices in a generation.

Keep ReadingShow less
© Copyright 2025 Garavi Gujarat Publications Ltd & Garavi Gujarat Publications USA Inc